Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer.

Autor: Hedayat S; Division of Molecular Pathology and Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom., Cascione L; Bioinformatics Core Unit, Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Bellinzona, Switzerland.; Swiss Institute of Bioinformatics, Bellinzona, Switzerland., Cunningham D; Department of Medicine, The Royal Marsden Hospital, London and Sutton, United Kingdom., Schirripa M; Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy., Lampis A; Division of Molecular Pathology and Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom., Hahne JC; Division of Molecular Pathology and Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom., Tunariu N; Department of Radiology, The Royal Marsden Hospital, London and Sutton, United Kingdom., Hong SP; Division of Surgery and Cancer, Imperial College London, London, United Kingdom., Marchetti S; Division of Molecular Pathology and Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom., Khan K; Division of Molecular Pathology and Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.; Department of Medicine, The Royal Marsden Hospital, London and Sutton, United Kingdom., Fontana E; Division of Molecular Pathology and Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom., Angerilli V; Division of Molecular Pathology and Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.; Department of Medicine, Surgical Pathology Unit, University of Padua, Padua, Italy., Delrieux M; Division of Molecular Pathology and Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom., Nava Rodrigues D; Division of Molecular Pathology and Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom., Procaccio L; Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy., Rao S; Department of Medicine, The Royal Marsden Hospital, London and Sutton, United Kingdom., Watkins D; Department of Medicine, The Royal Marsden Hospital, London and Sutton, United Kingdom., Starling N; Department of Medicine, The Royal Marsden Hospital, London and Sutton, United Kingdom., Chau I; Department of Medicine, The Royal Marsden Hospital, London and Sutton, United Kingdom., Braconi C; Department of Medicine, The Royal Marsden Hospital, London and Sutton, United Kingdom.; Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.; Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom., Fotiadis N; Department of Interventional Radiology, The Royal Marsden Hospital, London, United Kingdom., Begum R; Department of Medicine, The Royal Marsden Hospital, London and Sutton, United Kingdom., Guppy N; Breast Cancer Now Nina Barough Pathology Core Facility, The Institute of Cancer Research, London, United Kingdom., Howell L; Division of Molecular Pathology and Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom., Valenti M; Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Cribbes S; Revvity, Waltham, Massachusetts., Kolozsvari B; Sartorius, London, United Kingdom., Kirkin V; Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Lonardi S; Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy., Ghidini M; Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Passalacqua R; Oncology Unit, ASST Cremona, Cremona, Italy., Elghadi R; Division of Surgery and Cancer, Imperial College London, London, United Kingdom., Magnani L; Division of Surgery and Cancer, Imperial College London, London, United Kingdom., Pinato DJ; Division of Surgery and Cancer, Imperial College London, London, United Kingdom.; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy., Di Maggio F; Division of Surgery and Cancer, Imperial College London, London, United Kingdom.; Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Naples, Italy.; CEINGE-Biotecnologie Avanzate Francesco Salvatore, Via Gaetano Salvatore, Naples, Italy., Ghelardi F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Sottotetti E; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Vetere G; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Ciracì P; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Vlachogiannis G; Division of Molecular Pathology and Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.; Division of Surgery and Cancer, Imperial College London, London, United Kingdom., Pietrantonio F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Cremolini C; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Cortellini A; Division of Surgery and Cancer, Imperial College London, London, United Kingdom.; Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy., Loupakis F; Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy., Fassan M; Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy.; Department of Medicine, Surgical Pathology Unit, University of Padua, Padua, Italy., Valeri N; Division of Molecular Pathology and Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.; Department of Medicine, The Royal Marsden Hospital, London and Sutton, United Kingdom.; Division of Surgery and Cancer, Imperial College London, London, United Kingdom.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 May 15; Vol. 30 (10), pp. 2140-2159.

Expression and interdependencies of pluripotency factors LIN28, OCT3/4, NANOG and SOX2 in human testicular germ cells and tumours of the testis

Autor: Gillis, Ad, Stoop, Hans, Biermann, Katharina, van Gurp, RJHLM (Ruud), Swartzman, E, Cribbes, S, Ferlinz, A, Shannon, M, Oosterhuis, Wolter, Looijenga, LHJ (Leendert)

Publikováno v: International Journal of Andrology, 34(4), E160-E174. Wiley-Blackwell Publishing Ltd

OCT3/4, NANOG, SOX2 and, most recently, LIN28 have been identified as key regulators of pluripotency in mammalian embryonic and induced stem cells, and are proven to be crucial for generation of the mouse germ-cell lineage. These factors are a hallma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::e90c990d531b0e4be622b61b327cf034
https://pure.eur.nl/en/publications/7a3c3591-2f2a-4ba3-8f45-afa8b724da48

Real-time viability and apoptosis kinetic detection method of 3D multicellular tumor spheroids using the Celigo Image Cytometer.

Autor: Kessel S; Department of Technology R&D, Nexcelom Bioscience LLC, Lawrence, Massachusetts, 01843., Cribbes S; Department of Technology R&D, Nexcelom Bioscience LLC, Lawrence, Massachusetts, 01843., Bonasu S; Department of Technology R&D, Nexcelom Bioscience LLC, Lawrence, Massachusetts, 01843., Rice W; Department of Technology R&D, Nexcelom Bioscience LLC, Lawrence, Massachusetts, 01843., Qiu J; Department of Technology R&D, Nexcelom Bioscience LLC, Lawrence, Massachusetts, 01843., Chan LL; Department of Technology R&D, Nexcelom Bioscience LLC, Lawrence, Massachusetts, 01843.

Publikováno v: Cytometry. Part A : the journal of the International Society for Analytical Cytology [Cytometry A] 2017 Sep; Vol. 91 (9), pp. 883-892. Date of Electronic Publication: 2017 Jun 15.

A Novel Multiparametric Drug-Scoring Method for High-Throughput Screening of 3D Multicellular Tumor Spheroids Using the Celigo Image Cytometer.

Autor: Cribbes S; 1 Department of Technology R&D, Nexcelom Bioscience LLC, Lawrence, MA, USA., Kessel S; 1 Department of Technology R&D, Nexcelom Bioscience LLC, Lawrence, MA, USA., McMenemy S; 1 Department of Technology R&D, Nexcelom Bioscience LLC, Lawrence, MA, USA., Qiu J; 1 Department of Technology R&D, Nexcelom Bioscience LLC, Lawrence, MA, USA., Chan LL; 1 Department of Technology R&D, Nexcelom Bioscience LLC, Lawrence, MA, USA.

Publikováno v: SLAS discovery : advancing life sciences R & D [SLAS Discov] 2017 Jun; Vol. 22 (5), pp. 547-557. Date of Electronic Publication: 2017 Jan 31.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.